

Roger D. Tung
President and Chief Executive Officer

Roger D. Tung, Ph.D. is our co-founder and has served as our President and Chief Executive Officer and as a member of our board of directors since April 2006. Before Concert, Dr. Tung was a founding scientist at Vertex Pharmaceuticals, a pharmaceutical company, where he was employed from 1989 to 2005, most recently as its Vice President of Drug Discovery. Prior to Vertex, he held various positions at Merck, Sharp & Dohme Research Laboratories, a global healthcare provider, and The Squibb Institute for Medicinal Chemistry. Dr. Tung received a B.A. in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison.

Marc Becker
Chief Financial Officer

Mr. Marc Becker has served as our Chief Financial Officer since January 2018. Prior to joining Concert, Mr. Becker served as Senior Vice President and Chief Financial Officer at CRISPR Therapeutics from February 2016 to September 2017. Prior to joining CRISPR Therapeutics, Mr. Becker served as Chief Financial Officer and Senior Vice President of rEVO Biologics, a biopharmaceutical from January 2012 to February 2016. Before rEVO, Mr. Becker spent 10 years at Genzyme Corporation, most recently serving as Finance Director for the UK and Ireland before returning to the United States to become the Vice President of Finance for Genzyme's Renal and Endocrine business. He also serves on the Board of Directors of Food for Free, a non-profit organization in Cambridge, MA. Mr. Becker began his career in auditing and commercial lending for financial services firms, KPMG and BankBoston. Mr. Becker holds a BS from the University of Massachusetts, an MBA from Babson College and was licensed as a CPA.

James Cassella
Chief Development Officer

Dr. James Cassella has served as our Chief Development Officer since February 2015. Prior to joining Concert, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc. from June 2004 to January 2015. Prior to Alexza Pharmaceuticals, Dr. Cassella held various management positions at Neurogen Corporation, including Senior Vice President, Clinical Research and Development. Before joining the biotechnology industry, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Dr. Cassella received his Ph.D. in Physiological Psychology from Dartmouth College, completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and received a B.A. in psychology from the University of New Haven.

Lynette A. Herscha
General Counsel

Ms. Lynette Herscha has served as our General Counsel and Secretary since June 2017 and was our Vice President and Associate General Counsel from July 2014 to June 2017. Prior to joining Concert, she held senior legal positions at Momenta Pharmaceuticals, Inc., a public biotechnology company, and Phase Forward, Incorporated, a public technology company. Ms. Herscha began her career at the law offices of Fulbright & Jaworski. Ms. Herscha earned her J.D. from Boston University School of Law and her B.A. from Boston University.

Nancy Stuart
Chief Operating Officer

Ms. Nancy Stuart has served as our Chief Operating Officer since October 2007 and was our Senior Vice President, Corporate Strategy and Operations from July 2006 to October 2007. Prior to joining Concert Ms. Stuart held various business operations and business development positions at Amgen Inc., a biopharmaceutical company, Kinetix Pharmaceuticals, Inc., a pharmaceutical company subsequently acquired by Amgen, Scion Pharmaceuticals, Inc., a pharmaceutical company, Vertex Pharmaceuticals, a pharmaceutical company and Genzyme Corporation, a biotechnology company subsequently acquired by Sanofi S.A. Ms. Stuart holds a B.S. from the University of Michigan, and an M.B.A. from the Simmons College Graduate School of Management.

Justine E. Koenigsberg

Senior Vice President, Corporate Communications and Investor Relations

Ms. Koenigsberg joined Concert in March 2008 and currently serves as Senior Vice President, Corporate Communications and Investor Relations. She has more than 20 years corporate communications and investor relations experience within the biotechnology industry. Prior to joining Concert she held senior communication roles at ViaCell, Inc. and Transkaryotic Therapies (TKT) where she developed and implemented a variety of communication strategies and managed their investor relations programs. Prior to TKT, she held communications positions at Vertex Pharmaceuticals. Ms. Koenigsberg is a member of the National Investors Relations Institute and served on the Board of Directors and as a Past-President of its Boston Chapter. She holds a B.S. in Business Administration from Northeastern University.

Virginia Braman

Vice President, Clinical Development

Ms. Braman joined Concert in April 2010 and currently serves as Vice President, Clinical Development. She has over 25 years of research, development and clinical experience. Prior to Concert, she had a variety of clinical roles across a number of therapeutic areas at Cambridge BioScience, ImmunoGen, Cardiokine, and NitroMed. At NitroMed, she managed the Phase 3 clinical trial for BiDil® for the treatment of heart failure, which led to FDA approval. Prior to joining the biotechnology industry, Ms. Braman conducted research using monoclonal antibodies at both Beth Israel Hospital in Boston and University of Pennsylvania Medical School. Ms. Braman holds a B.S. in Biology from Northeastern University.

Christine Boisclair

Vice President, Regulatory Affairs

Ms. Boisclair joined Concert in June 2016 as Vice President, Regulatory Affairs with more than 30 years Regulatory Affairs experience in the biopharmaceutical industry and across multiple therapeutic areas. Prior to joining Concert, Ms. Boisclair was Vice President, Regulatory Affairs at Forum Pharmaceuticals. Before joining Forum Pharmaceuticals Ms. Boisclair held management roles at several companies including Insmad Inc, Agennix Inc, OSI Pharmaceuticals Inc, Genzyme Corporation, Immulogic Pharmaceuticals and Parexel International. Ms. Boisclair began her regulatory career at Searle Pharmaceuticals and Glaxo in the UK. She received a Bachelor of Science Honors Degree in Biochemistry from the University of York in the UK.

Julie Liu, Ph.D.

Vice President, Research and Development Management

Dr. Liu joined Concert in January 2007 and currently serves as Vice President, Research and Development Management. She has more than 18 years of experience in the pharmaceutical and biotechnology industry in the fields of medicinal chemistry, research management, and development program management. Prior to joining Concert, Dr. Liu worked at Millennium Pharmaceuticals in the areas of oncology, inflammation, and metabolic disease. She earned her B.S. in Chemistry with honors and distinction from the University of North Carolina at Chapel Hill, and her Ph.D. in Organic Chemistry from the University of California, Berkeley.

Scott Weintraub

Vice President, Commercial and Product Strategy

Mr. Weintraub joined Concert in August 2016 and currently serves as Vice President, Commercial and Product Strategy. Mr. Weintraub has more than 17 years commercial experience, including strategic product assessment, brand positioning, commercial life cycle management and sales and marketing. Prior to joining Concert he was Vice President of Product Strategy and Marketing at Forum Pharmaceuticals. He also served as Senior Director of Marketing at Sunovion Pharmaceuticals and held sales and marketing positions at AstraZeneca. He holds a B.S. in Finance and Marketing from Florida State University and an MBA in Health Administration and Policy from University of Miami.